A trial fibrillation (AF) is the major risk factor for cardioembolic stroke.
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LTL Measurement
The genomic DNA of peripheral blood leukocytes was isolated to measure LTL by a real-time polymerase chain reaction-based method 13 as described in the expanded Methods section of this article.
Statistical Analysis
Continuous and categorical variables were compared between AF stroke and nonstroke patients using the Student's t and the χ 2 tests, respectively. Correlation was assessed using Spearman correlation coefficient.
A nonconditional logistic regression model was used to evaluate the LTL-associated stroke risk. We assessed the goodness of fit with the Hosmer-Lemeshow goodness-of-fit statistic. The main independent variable was LTL, of which the 10th and 5th percentiles according to the nonstroke group values were used as cut-offs. Univariate and sex, hypertension, diabetes mellitus, heart failure, and age-adjusted multivariate models were performed. Stata/SE 13.1 (StataCorp, College Station, TX) was used for the analyses. Table 1 shows the patients' clinical characteristics. Seventeen patients were finally excluded because of lack of DNA. Patients with Stroke exhibited higher CHADS 2 values. There were no differences in sex, age, international normalized ratio, or creatinine. Remarkably, LTL was significantly shorter in the patients with stroke (Table 1 ; Figure I in the online-only Data Supplement).
Results
Because advanced age has been associated with telomere shortening, 3 we studied their correlation in our population. We found no significant correlation between age and LTL (ρ=0.1; P=0.16). This unexpected result may be explained by the narrow range of age of our cohort.
To gain insights into the cardioembolic stroke risk associated with telomere shortening, nonconditional logistic regression models were applied, using the 10th and 5th percentiles of the nonstroke group LTL values as cut-offs. As shown in Table 2 , LTL below the 10th percentile significantly increased the risk of cardioembolic stroke. Interestingly, the risk remained unchanged when sex and CHADS 2 components were used as confounders. It was noteworthy that the risk became higher when the 5th percentile was applied. Thus, short LTL independently and dose-dependently increases the cardioembolic stroke risk.
Discussion
New tools are needed to improve the assessment of cardioembolic stroke risk in patients with AF. We provide evidence that, among the patients with AF, cardioembolic stroke risk is dose-dependently associated with short LTL. Remarkably, the risk seems to be independent of traditional stroke risk factors.
The association between LTL and stroke has been a matter of controversy. [8] [9] [10] [11] [12] However, those studies never specifically addressed the cardioembolic subtype: 2 reports excluded these patients, 8, 11 and the others included only a small proportion of them within the study population. 9, 10, 12 Ours is the first study aimed to establish a relationship between LTL and this specific stroke subtype. Furthermore, our cohort presents an additional advantage: our control group consists of patients with AF, unlike the control groups of the cited studies that were made up of healthy subjects. Thus, we have found an independent association under rather severe analytic conditions. Also controversial is the real role played by short telomeres in cardiovascular diseases: in spite of the fact that short telomeres seem to play a key role by driving cells into senescence and apoptosis, 3, 4 there are studies that do not support causality.
14 Our finding that the cardioembolic stroke risk displayed a dose-dependency according to LTL values would provide support for the causative hypothesis.
Our study has limitations. Its retrospective nature precludes definitive conclusions about the prognostic power of LTL in predicting the cardioembolic stroke risk. Indeed, we cannot definitely establish that telomere shortening actively plays a role in the pathogenesis of cardioembolic stroke. However, our study was performed in a relatively small population. Nevertheless, we consider that the strength and dose-dependency of the observed results provide enough arguments to establish a sound relationship between LTL and cardioembolic stroke.
In summary, our findings indicate that short LTL was independently associated with higher cardioembolic stroke risk in patients with AF. Our findings encourage prospective studies to confirm that LTL constitutes an attractive biomarker to help in the decision to start anticoagulant treatment in patients with AF.
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SUPPLEMENTAL MATERIAL EXPANDED MATERIALS AND METHODS
Cardioembolic stroke diagnosis criteria
Cardioembolic stroke was defined as the sudden onset of a focal neurologic deficit in a location consistent with the territory of a major cerebral artery and confirmed by imaging techniques (magnetic resonance imaging or X-ray computed tomography). The cardioembolic origin was allocated if atrial fibrillation (AF) was present at the time of stroke diagnostic and there was not present a carotid artery lesion occluding more than 50% of the lumen diameter in the side of the infarction according with the TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment).
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Patients inclusion and exclusion criteria
The inclusion criteria were AF diagnosed by electrocardiography, which lasted more than three months and, in the case of the stroke patients, was diagnosed before or at the time of the stroke. Patients were excluded from the study if they met any of the following criteria: carotid artery lesion occluding more than 50% of the lumen vessel diameter in the side of the infarction, cancer in progress, leukocytosis (more than 7,000 cells/mL), leukopenia (less than 3,500 cells/mL), history of venous thromboembolism or acute coronary syndrome in the last three months, infection, autoimmune disease or surgery. Renal failure (creatinine value more than double the normal value), oral contraceptive use, hormonal therapy, and corticoid consumption were also exclusion criteria. Demographic variables [age, sex, AF diagnosis date, stroke date, CHADS 2 , international normalized ratio (INR) and creatinine] were collected at the time of the blood test.
Leukocyte telomere length (LTL) measurement
Genomic DNA of peripheral blood leukocytes was isolated using standard protocols to determine LTL using a real-time quantitative PCR (RT-PCR)-based method previously described by Cawthon.
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In brief, LTL was the ratio between the copy number of telomere repeats (T) and that of the single-copy gene ribosomal protein, large PO (RPLPO) (S), used as a quantitative control. The T/S ratio was calculated as follows: [2 Ct (telomeres)/2 Ct (single copy gene)]=2
−ΔCt (C t , threshold cycle) because the amount of the PCR product approximately doubles in each cycle of the PCR. On the other hand, a calibration curve of the same DNA reference sample (from 50 to 3.125 ng/μL in 2-fold dilutions) was always included for each measurement as a standard to control the dayto-day variations.
RT-PCR was performed using an ABI-Applied Biosystems 7900 HT thermal cycler (Applied Biosystems, Foster City, CA, USA). QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA, USA) was used as master mix. Standard curves with linearity R 2 > 0.98 were accepted. All samples were run in triplicate, and the ones exhibiting C t differences among triplicates higher than 0.5 cycles were discarded. A no-template control was also included for quality control. The intra-assay coefficient of variation between triplicates for telomeres and for the single copy gene were 1.95 and 0.95% respectively. DNA reference sample was used to calculate the inter-assay coefficient of variation, which was 1.34 and 1.08% for telomeres and for the single copy gene respectively. Thus, the small coefficients of variation support the reliability of this procedure. Figure I non-stroke stroke Figure I . Distribution of leukocyte telomere length (LTL) in AF patients. LTL was calculated as the natural log of the ratio between the copy number of telomere repeats and that of the single-copy gen. RU, relative units.
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